Synthorx fortifies $63m series C

Retrieved on: 2018-04-30 19:03:45

Tags for this article:

Nucleobases

Organic compounds

Click the tags to see associated articles and topics

Synthorx fortifies $63m series C. View article details on hiswai:

Excerpt

<div>Healthcare-focused investment firm OrbiMed led the round, which also featured <b>Avalon Ventures</b>, RA Capital Management and Correlation Ventures. Synthorx is exploiting new genetic DNA pairings to enhance the formulation of interleukin-2 (IL-2), a drug currently hindered by safety concerns which ...</div>

Article found on:

View Original Article